

The comet assay with standard aquatic test organisms as an alternative test system for environmental risk assessment of human pharmaceuticals

Marwin Jafari¹, Maria Vogt¹, Elke Eilebrecht¹, Lena Kosak¹, Jasmin Brueckner², Ute Kuehnen², Kathi Westphal-Settele², Karsten Schlich¹

¹Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Schmallenberg, Germany

²German Environment Agency, Dessau-Roßlau, Germany

E-mail contact: karsten.schlich@ime.fraunhofer.de

Background

Human pharmaceuticals find their way into aquatic ecosystems e.g. via municipal wastewater, where they pose a potential threat to aquatic organisms. A comprehensive environmental risk assessment (ERA) is necessary to minimize their risks. In accordance to the guidance on human pharmaceuticals (EMA, 2006) for an ERA, effects on aquatic organisms are determined based on standardized guidelines including (OECD 201, 210 and 211). In a previous project (German Environmental Agency, FKZ 3718 65 420 1) alternative test systems for an ERA were identified. One of the identified test systems was the Comet Assay, a genotoxicity test that quantifies DNA damage by measuring the fraction of DNA that migrates out of a nucleus during gel electrophoresis (Tail intensity or TI%), with environmentally relevant organisms. The aim of this study was to establish the comet assay as a genotoxicity assay for the environmental risk assessment of human pharmaceuticals, both *in vivo* with *Daphnia magna* and *in vitro* with a cell line of *Danio rerio* liver cells (ZF-L).

Comet assay

The comet assay is a genotoxicity assay applicable to practically all eukaryotic cells, capable of visualizing the frequency of DNA strand breaks [1].

- Cells are mixed with agarose
- Agarose gels are placed onto a microscopy slide
- Lysis solution removes membranes
- An alkaline solution causes DNA to unwind and separate into single strands
- Electrophoresis draws loose DNA fragments out of the nucleus
- Endpoint: Tail Intensity in percent, fraction of DNA in the comet tail

Low frequency of strand breaks:
Low Tail Intensity, more DNA in Comet "Head"




Figure 1: Comet Assay with ZF-L cells (Control)

High frequency of strand breaks:
High Tail Intensity, more DNA in Comet "Tail"




Figure 2: Comet Assay with ZF-L cells 48 h exposition with 50 mg/L Cyclophosphamid

Method

| | <i>Daphnia magna</i> | <i>Danio rerio</i> liver cell line ZF-L |
|--------------------|--|---|
| Exposition | <ul style="list-style-type: none"> 15 individuals aged <24h per replicate Exposition in 50 mL beakers 48 hours of exposition Triplicates | <ul style="list-style-type: none"> approx. 100 000 cells per replicate Exposition in 24 well plate 48 hours of exposition Triplicates |
| Tissue preparation | <ul style="list-style-type: none"> Mechanical homogenization with glass microbeads Filtration with a 50 µm PET filter | <ul style="list-style-type: none"> Trypsination |
| Comet Assay | <ul style="list-style-type: none"> Mixing of cell suspension with low melting point agarose Placement of 6 gels per replicate on agarose coated microscopy slides 60 minutes lysis 20 min incubation in alkaline gel electrophoresis solution 20 min gel electrophoresis at 24 Volt | |

Results




Figure 3: Tail Intensity over concentration of reference genotoxicants Hydrogen Peroxide (left) and Cyclophosphamid (right) after the comet assay with ZF-L (top and middle) and *Daphnia* cells (bottom)

Table 1: Lowest observable effect concentrations (LOEC) for human pharmaceuticals determined via the comet assay with *D. magna* cells and *D. rerio* liver cells (LOEC was determined as the lowest concentration showing a statistically significant difference to control)

| Substance name | Use | LOEC in <i>D. magna</i> comet assay | LOEC in ZF-L in vitro comet assay |
|-------------------|--------------|-------------------------------------|-----------------------------------|
| Abamaciclib | Chemotherapy | > 10 mg/L | > 10 mg/L |
| Cyclophosphamid | Chemotherapy | > 100 mg/L | 12.5 mg/L |
| Dabrafenib | Chemotherapy | > 50 mg/L | > 15 mg/L |
| Edoxaban | Cardiology | > 50 mg/L | > 25 mg/L |
| Imatinib Mesylate | Chemotherapy | > 50 mg/L | 100 mg/L |
| Palbociclib | Chemotherapy | > 10 mg/L | > 10 mg/L |
| Pitavastatin | Cardiology | 50 mg/L | > 50 mg/L |
| Ribociclib | Chemotherapy | > 40 mg/L | Not determined yet |
| Rosuvastatin | Cardiology | > 5 mg/L | Not determined yet |

Conclusions

- Both the *in vivo* and *in vitro* method were successfully established and confirmed by testing cyclophosphamide (DNA alkylating agent) and hydrogen peroxide (reactive oxygen species) as reference substances.
- The *in vivo* method showed a low sensitivity, while the *in vitro* method appeared to be more sensitive.
- Test concentrations (mg/L range) were above the predicted environmentally relevant concentrations (ng/L range) and above the data of chronic daphnia and fish tests.
- The comet assay appears to be appropriate to assess the genotoxicity of a test substance, but due to the low sensitivity compared to the established test systems (e.g. OECD 210/211) it is not necessarily useful for an ERA of human pharmaceuticals.

Acknowledgement - The project is funded by the German Environment Agency (FKZ: 3718 65 420 2).

References :

[1] Ostling, O.; Johanson, K. J. (1984): Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. In Biochemical and Biophysical Research Communications 123 (1), pp. 291–298. DOI: 10.1016/0006-291x(84)90411-x.